C4 Therapeutics (CCCC) Receivables (2019 - 2026)

C4 Therapeutics has reported Receivables for 8 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 64.09% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 64.09% YoY), and the FY2025 full-year result was $2.4 million, down 22.6% from the prior year.
• Receivables for Q1 2026 stood at $2.9 million, up from $2.4 million in the prior quarter.
• The five-year high for Receivables was $13.6 million in Q1 2024, with the low at $500000.0 in Q3 2023.
• Average Receivables over 5 years is $4.1 million, with a median of $2.2 million recorded in 2025.
• Year-over-year, Receivables slumped 74.23% in 2022 and surged 2475.57% in 2024.
• Tracing CCCC's Receivables over 5 years: stood at $1.5 million in 2022, then jumped by 701.02% to $11.8 million in 2023, then plunged by 73.71% to $3.1 million in 2024, then decreased by 22.6% to $2.4 million in 2025, then increased by 20.07% to $2.9 million in 2026.
• The last three Receivables figures came in at $2.9 million (Q1 2026), $2.4 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.

Peer Comparison